...
【24h】

Loss of heterozygosity: a potential tool in management of oral premalignant lesions?

机译:杂合性丧失:治疗口腔癌前病变的潜在工具?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Oral leukoplakia, a heterogeneous group of lesions, demonstrates a varying degree of risk for cancer progression. Histology (presence and degree of dysplasia), the current gold standard for assessing this risk, is reasonably effective in judging the malignant risk of high-grade pre-invasive lesions. It is, however, a poor predictor for lesions without dysplasia, or with minimal dysplasia, as only a few of these lesions will progress to cancer. This poses an enormous dilemma for clinicians as to whether these lesions should be aggressively treated or not. Recent studies show that loss of specific chromosomal regions (loss of heterozygosity, LOH) that contain known or presumptive tumor suppressor genes is an early predictor of subsequent progression of oral premalignant lesions. Incorporation of LOH findings into staging of oral premalignancy could improve our ability to identify and manage high-risk premalignant lesions, particularly those with relatively benign histology but high-risk genetic changes (high-risk LOH pattern).
机译:口腔白斑是一组异质性病变,表现出不同程度的癌症进展风险。组织学(不典型增生的程度和程度)是当前评估这种风险的金标准,在判断高级别浸润前病变的恶性风险方面相当有效。但是,对于没有发育异常或具有最小增生的病变而言,它是不良的预测指标,因为这些病变中只有少数会发展为癌症。对于临床医师而言,是否应积极治疗这些病变,这是一个巨大的难题。最近的研究表明,含有已知或推测的抑癌基因的特定染色体区域的丢失(杂合性缺失,LOH)是口腔癌前病变后续进展的早期预测指标。将LOH研究结果纳入口腔癌前分期可以提高我们识别和处理高风险癌前病变的能力,尤其是那些组织学相对良性但遗传风险高的人(高风险LOH模式)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号